References
- Canevari A., Pagnucco G., Castelli Bonfichi G. M., Santagostino A., Bernasconi C. The antiemetic therapy in antineoplastic chemotherapy. “Attualità di chemioterapia antineoplastica in Ematologia”, C. Bernasconi. EMP Publishers, Pavia 1987; 259–66
- Borison H. L., McCarthy L. E. Neuropharmacology of chemotherapy induced emesis. Drugs 1983; 25: 8
- Laszlo J. Nausea and vomiting as major complications of Cancer chemotherapy. Drugs 1983; 25(Suppl. 1)1
- Bakowski M. T. Advances in anti-emetic therapy. Cancer Treatment Reviews 1984; 11: 237
- Peroutka S. J., Snyder S. H. Antiemetics: neurotransmitter receptor binding predicts therapeutic actions. The Lancet 1982; 20: 658
- Pollera C. F., Giannarelli D. Prognostic factors influencing cis-platin induced emesis. Cancer 1989; 64: 1117
- Roila F., Tonato M., Basurto C. Antiemetic activity of high doses of metoclopramide combined with methyl-prednisolone versus metoclopramide alone in cisplatin-treated cancer patients: a randomized double-blind trial of the Italian Oncology Group for Clinical Research. J Clin Oncol 1987; 5: 141
- Depierre A., Lebeau B., D'Allens French H., Pneumology Group for Ondansetron Study. Comparison of ondansetron with a combined regimen of alizapride and methyl-prednisolone in the prophylaxis of cisplatin-induced emesis in patient with lung cancer. Proceedings of the 3rd International Congress of Neo-adjuvant chemotherapy, Ondansetron and Chemotherapy induced emesis, Paris, Glaxo, 1991
- Droz J. P., Lane-Allman E. Effective emesis control with ondansetron in cisplatin treated patients refractory to routinely used anti-emetics. European Journal of Cancer 1991, Suppl. 2: S293
- Tonato M., Roila F. Antiemetics Drugs. “Medical Oncologic Therapy”, A. Santoro, G. Bonadonna. Napoli, S.E.S. Publishers. 1990; 133–48
- Clark R. A., Gralla R. J., Kris M. G., et al. Exploring very high doses of metoclopramide (4–6mg/kg): Preservation of efficacy and safety with only a single dose in a combination antiemetic regimen. Proc Am Soc Clin Oncol 1989; 8: 330
- Kris M. G., Gralla R. J., Tyson L. B., et al. Controlling delayed vomiting: double blind randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin. J Clin Oncol 1989; 7: 108
- Harousseau J. L., Gisselbrecht C., Paillarse J. M., French Haematology Group for the study of Ondansetron (1991) . Comparison of ondansetron and alizapride in the prophylaxis of lymphoma chemotherapy induced emesis. Proceedings of 6th European Conference on Clinical Oncology and Cancer Nursing, Firenze, 1991, 52
- Basurto C, Roila F., De Favero A., et al. A prospective randomized double-blind cross-over study comparing the antiemetic activity of alizapride and metoclopramide in patients receiving cisplatin chemotherapy. Cancer Invest 1988; 6: 475
- Joss R. A., Galeazzi R. L., Bischoff A. K., et al. The antiemetic activity of high-dose alizapride and high-dose metoclopramide in patients receiving cancer chemotherapy: a prospective, randomized, double-blind trial. Clin Pharmacol Ther 1986; 39: 619
- Sailer R., Hellenbrecht D. Comparison of the antiemetic efficacy of two high-dose benzamides, metoclopramide and aliza pride, against cisplatin-induced emesis. Cancer Treat Rep 1985; 69: 1301
- Kris M. G., Gralla R. J., Clark R. A., et al. -Anti-emetic control and prevention of side effects of anticancer therapy with lorazepam or diphenhydramine when used in combination with metoclopramide plus dexamethasone. A double-blind, randomized trial. Cancer 1987; 60: 2816
- Tyers M. B., Bunce K. T., Humphrey P. P. A. Pharmacological and anti-emetic properties of ondansetron. Eur J Cancer Clin Oncol 1989; 25(Suppl. 1)15
- Campora E., Merlini L., Giudici S., et al (1991) Randomized trial of ondansetron and dexamethasone versus metoclopramide, dexamethasone and orphenadrine for the control of acute and delayed FEC-FAC induced emesis. Proceedings of 6th European Conference on Clinical Oncology and Cancer Nursing, Firenze, 1991, 55
- Dicato M., Ries F., Steffen M. J., Thoma L. (1991) Ondansetron is highly efficient in preventing acute emesis in high dose 4-epirubicin therapy. Proceedings of 6th European Conference on Clinical Oncology and Cancer Nursing, Firenze, 1991, 56
- Soukop M. (1991) Control of emesis and quality of life during multiple-cycles chemotherapy in the treatment of breast cancer. Proceedings of the 6th European Conference on Clinical Oncology and Cancer Nursing, Firenze, 1991, 29–37
- Jiigens H., Europea paediatric Emesis Study Group (1991) . Ondansetron as prophylaxis for chemotherapy-and radiotherapy-induced emesis in children. Proceedings of the 6th European Conference on Clinical Oncology and Cancer Nursing, Firenze, 1991, 21–25
- Bosi A., Guidi S., Saccardi R., et al (1991) Antiemetic prophylaxis with Ondansetron in BMT. proceedings of the 33rd Congress of the Italian Society of Hematology, Verona, 1991, 14